INTRODUCTION
While chemotherapy is a primary treatment in the management of cancer, its acute and/or persistent adverse effects on the functioning of the human nervous system can, at times, have profound effects on patient quality of life. These potential adverse effects include seizures; severe ataxia; acute encephalopathy characterized by confusion, sleep disturbance, and agitation that may resolve after treatment; and quadriplegia. Less severe problems are more common, including chronic cognitive dysfunction and peripheral neuropathy that less often impair patient function permanently and more often cause disturbing paresthesia, ataxia, pain, autonomic dysfunction, or a combination of these. Table 1 lists many neurotoxic effects of commonly used anticancer agents.
Any consideration of cancer therapy's toxicity on the nervous system must take into account the impact of the disease itself on the nervous system. Cancer, through the host's response to the illness, has widespread nonmetastatic effects on both the central and the peripheral nervous systems, which makes study of neurotoxicity challenging. Evidence of peripheral neuropathy can be found in more than half of patients with lung cancer before initiation of any therapy, if looked for carefully.
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Similarly, central nervous system effects are widespread, particularly cognitive impairment resulting from vascular effects and/or infl ammatory mediator activation or local cytokine release. Beyond these indirect effects, neoplasms can, of course, metastasize to the nervous system, which must be considered in any suspected instance of neurotoxicity. Unfortunately, the mechanisms by which cytoreductive therapies work are often intertwined with their side effects, challenging the rational management of nervous system toxicity related to anticancer treatment. Preexisting neurological disease, which may have been subclinical, may also have a signifi cant impact on neurological toxicity. Moreover, neurotoxicity from cancer therapy presents a greater risk for neonates and elderly patients than for other age groups.
